BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 18165851)

  • 1. Imaging, subjective complaints, and MCI: 30 years before.
    Galluzzi S; Frisoni GB
    J Nutr Health Aging; 2008 Jan; 12(1):80S-3S. PubMed ID: 18165851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain-imaging surrogate markers for detection and prevention of age-related memory loss.
    Small GW
    J Mol Neurosci; 2002; 19(1-2):17-21. PubMed ID: 12212776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment.
    Lombardi G; Crescioli G; Cavedo E; Lucenteforte E; Casazza G; Bellatorre AG; Lista C; Costantino G; Frisoni G; Virgili G; Filippini G
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009628. PubMed ID: 32119112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of neuroimaging to detect early brain changes in people at genetic risk for Alzheimer's disease.
    Small GW
    Adv Drug Deliv Rev; 2002 Dec; 54(12):1561-6. PubMed ID: 12453673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impact of (11)C-Pittsburgh compound-B positron emission tomography carried out in addition to magnetic resonance imaging and single-photon emission computed tomography on the diagnosis of Alzheimer's disease in patients with dementia and mild cognitive impairment.
    Omachi Y; Ito K; Arima K; Matsuda H; Nakata Y; Sakata M; Sato N; Nakagome K; Motohashi N
    Psychiatry Clin Neurosci; 2015 Dec; 69(12):741-51. PubMed ID: 26085054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias.
    Bao YW; Chau ACM; Chiu PK; Shea YF; Kwan JSK; Chan FHW; Mak HK
    J Alzheimers Dis; 2021; 79(2):819-832. PubMed ID: 33361593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polygenic hazard score: an enrichment marker for Alzheimer's associated amyloid and tau deposition.
    Tan CH; Fan CC; Mormino EC; Sugrue LP; Broce IJ; Hess CP; Dillon WP; Bonham LW; Yokoyama JS; Karch CM; Brewer JB; Rabinovici GD; Miller BL; Schellenberg GD; Kauppi K; Feldman HA; Holland D; McEvoy LK; Hyman BT; Bennett DA; Andreassen OA; Dale AM; Desikan RS;
    Acta Neuropathol; 2018 Jan; 135(1):85-93. PubMed ID: 29177679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Education on Alzheimer's Disease-Related Neuroimaging Biomarkers in Healthy Controls, and Participants with Mild Cognitive Impairment and Alzheimer's Disease: A Cross-Sectional Study.
    Wada M; Noda Y; Shinagawa S; Chung JK; Sawada K; Ogyu K; Tarumi R; Tsugawa S; Miyazaki T; Yamagata B; Graff-Guerrero A; Mimura M; Nakajima S;
    J Alzheimers Dis; 2018; 63(2):861-869. PubMed ID: 29689728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional imaging in mild cognitive impairment and early Alzheimer's disease: is it pertinent?
    Ibáñez V; Deiber MP
    Front Neurol Neurosci; 2009; 24():30-38. PubMed ID: 19182460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What does imaging add to the management of Alzheimer's disease?
    Small GW
    CNS Spectr; 2004 Jul; 9(7 Suppl 5):20-3. PubMed ID: 15241296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid and tau imaging, neuronal losses and function in mild cognitive impairment.
    Barrio JR; Kepe V; Satyamurthy N; Huang SC; Small G
    J Nutr Health Aging; 2008 Jan; 12(1):61S-5S. PubMed ID: 18165848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuropathological changes in aging brain.
    Xekardaki A; Kövari E; Gold G; Papadimitropoulou A; Giacobini E; Herrmann F; Giannakopoulos P; Bouras C
    Adv Exp Med Biol; 2015; 821():11-7. PubMed ID: 25416106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo quantification of neurofibrillary tangles with [
    Pascoal TA; Shin M; Kang MS; Chamoun M; Chartrand D; Mathotaarachchi S; Bennacef I; Therriault J; Ng KP; Hopewell R; Bouhachi R; Hsiao HH; Benedet AL; Soucy JP; Massarweh G; Gauthier S; Rosa-Neto P
    Alzheimers Res Ther; 2018 Jul; 10(1):74. PubMed ID: 30064520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review on Alzheimer's disease classification from normal controls and mild cognitive impairment using structural MR images.
    Garg N; Choudhry MS; Bodade RM
    J Neurosci Methods; 2023 Jan; 384():109745. PubMed ID: 36395961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia.
    Lowe VJ; Wiste HJ; Senjem ML; Weigand SD; Therneau TM; Boeve BF; Josephs KA; Fang P; Pandey MK; Murray ME; Kantarci K; Jones DT; Vemuri P; Graff-Radford J; Schwarz CG; Machulda MM; Mielke MM; Roberts RO; Knopman DS; Petersen RC; Jack CR
    Brain; 2018 Jan; 141(1):271-287. PubMed ID: 29228201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimer's disease: a systematic review.
    Ruan Q; D'Onofrio G; Sancarlo D; Bao Z; Greco A; Yu Z
    BMC Geriatr; 2016 May; 16():104. PubMed ID: 27184250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is aging part of Alzheimer's disease, or is Alzheimer's disease part of aging?
    Swerdlow RH
    Neurobiol Aging; 2007 Oct; 28(10):1465-80. PubMed ID: 16876913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and prognosis of Alzheimer's disease using brain morphometry and white matter connectomes.
    Wang Y; Xu C; Park JH; Lee S; Stern Y; Yoo S; Kim JH; Kim HS; Cha J;
    Neuroimage Clin; 2019; 23():101859. PubMed ID: 31150957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations between quantitative [
    Timmers T; Ossenkoppele R; Wolters EE; Verfaillie SCJ; Visser D; Golla SSV; Barkhof F; Scheltens P; Boellaard R; van der Flier WM; van Berckel BNM
    Alzheimers Res Ther; 2019 Jul; 11(1):60. PubMed ID: 31272512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials.
    Grundman M; Petersen RC; Ferris SH; Thomas RG; Aisen PS; Bennett DA; Foster NL; Jack CR; Galasko DR; Doody R; Kaye J; Sano M; Mohs R; Gauthier S; Kim HT; Jin S; Schultz AN; Schafer K; Mulnard R; van Dyck CH; Mintzer J; Zamrini EY; Cahn-Weiner D; Thal LJ;
    Arch Neurol; 2004 Jan; 61(1):59-66. PubMed ID: 14732621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.